Skip to Content

Tricida, Inc.

Corporate Governance / Derivative

  • Date:
  • 4/9/2021
  • Company Name:
  • Tricida, Inc.
  • Stock Symbol:
  • TCDA
  • Status:
  • Investigating
  • Filing Date:
  • 1/6/2021

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire is investigating certain officers and directors of Tricida, Inc. following a class action complaint that was filled against Tricida on January 6, 2021.
 
The complaint alleges that throughout the class period defendants made materially false and misleading statements, and failed to disclose material adverse facts about the Company’s business, operational, and compliance policies. Specifically, defendants made false and/or misleading statements and failed to disclose to investors that: (i) Tricida’s NDA for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you are a long term stockholder,  have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below. There is no cost or obligation to you.

The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Tricida. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: